首页 >
法规速递
-
国家药监局药审中心关于发布《神经病理性疼痛治疗药物临床试验技术指导原则（试行）》的通告（2026年第9号）-2026/2/4
2026-02-05查看详情 > -
Document: Applications for new human medicines under evaluation: March 2026-2026/3/11
2026-03-12查看详情 > -
Page: Clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Scientific guideline-2026/4/9
2026-04-10查看详情 > -
Statistical Approaches to Establishing Bioequivalence-2026/5/29
2026-05-29查看详情 > -
Document: CVMP activities related to antimicrobials - Status report on EMA/CVMP activities (2021–2025) and EMANS 2028 Strategic Overview (Theme 4)-2026/7/10
2026-07-11查看详情 > -
Document: Presentation - AI and digital technologies transforming cardiovascular device in novation (S. Zenker)-2026/8/14
2026-08-17查看详情 > -
Regulatory and procedural guideline: European Medicines Agency post-authorisation procedural advice for users of the centralised procedure (updated)-2022/12/21
2022-12-21查看详情 > -
关于公开征求《细胞和基因治疗产品临床相关沟通交流技术指导原则（征求意见稿）》意见的通知-2023/7/25
2023-07-28查看详情 > -
Final Guidance: Clinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry-2024/2/29
2024-03-11查看详情 > -
Document: Aprepitant, hard capsules, 80mg, 125mg, 80+125mg and powder for oral suspension 125mg product-specific bioequivalence guidance-2025/1/31
2025-02-05查看详情 >
